Navigation Links
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
Date:12/10/2013

NORTHBROOK, Ill. and SAN DIEGO, Dec. 10, 2013 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Vical Incorporated (Nasdaq: VICL) today announced the initiation of a Phase 2 trial of ASP0113 in approximately 140 solid organ transplant (SOT) recipients.

The global, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of ASP0113 compared to placebo as measured by the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. The study will also evaluate the safety of ASP0113 in this patient population. Follow-up for each subject will continue for one year following enrollment.

"Following the initiation of our Phase 3 trial of ASP0113 in hematopoietic cell transplant (HCT) recipients in June, we are pleased to expand the ASP0113 program with this Phase 2 trial in SOT recipients," said Bernie Zeiher, Senior Vice President and Global Therapeutic Area Head of Immunology and Infectious Diseases at Astellas Pharma Global Development, Inc. "The unmet medical need to control CMV in transplant recipients remains high."

"We are very pleased with the collaborative nature of our relationship with Astellas and with the progress being made," said Vijay Samant, President and Chief Executive Officer of Vical.

Astellas is conducting the trial under an exclusive worldwide license agreement with Vical to develop and commercialize ASP0113. Vical is providing development, regulatory and manufacturing support.

About ASP0113
ASP0113 (formerly TransVax™) is an investigational bivalent DNA vaccine containing plasmids (closed loops of
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 "Whether ... potentially patients one day." In a single ... and chief scientific officer at Pfizer,s Centers for ... researchers and scientists fueling progress at America,s biopharmaceutical companies. ... to work side-by-side with academia, patient foundations and the ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... Results from two prospective, double-blind placebo controlled multi-center ... pooled European efficacy and safety data in patients with ... presented at the American Academy of Neurology,s (AAN) 61st ... by Merz Pharmaceuticals, which plans to file a Biologic ...
... AS, the human antibody,therapeutics company, announced today that ... were presented by its,collaboration partner Peregrine Pharmaceuticals at ... Cancer Research (AACR) 2009 held during April,18 - ... of PGN635 and PGN632,provided further confirmatory evidence that ...
Cached Medicine Technology:Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies 2
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... March 28, 2015 Pitching speed, player’s height, ... of shoulder and elbow injuries, according to new research released ... AOSSM ) Specialty Day. , “Our findings indicate that a ... increase in likelihood of a history of injury, a 10 ... 12% increase likelihood of a history of injury, and playing ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- ... must make in order to breast-feed is their sleep. But ... The study, published online Nov. 8 in the journal ... amount of time whether they were breast-feeding or formula-feeding. ...
... The use of statins among a group of postmenopausal ... to the results of a prospective analysis of data from ... results of our study are consistent with the majority of ... among users of statins," said Michael S. Simon, M.D., professor ...
... found that chemicals used to line junk food wrappers ... being ingested by people where they are contributing to ... acids or PFCAs are the breakdown products of chemicals ... ranging from kitchen pans to clothing to food packaging. ...
... (HealthDay News) -- Among certain patients with a history ... Pradaxa (dabigatran) appears to be as effective as the ... German research reveals. Specifically, the new study suggests ... stroke as effectively as warfarin among those facing an ...
... Breast cancer patients are more likely to have joint pain ... cancer, according to a study presented at the American College ... study is one of the first to identify factors that ... from AI therapy. AIs, the standard adjuvant therapy for ...
... an amphibious fish stays alive for up to two months on ... fishonly about an inch or two longthat live in temporary pools ... Florida. During dry seasons when their pools disappear, the fish hole ... stay moist, they can survive for extended periods out of water ...
Cached Medicine News:Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 3Health News:Statins did not reduce colorectal cancer in WHI analysis 2Health News:Dangerous chemicals in food wrappers likely migrating to humans: U of T study 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3Health News:Special skin keeps fish species alive on land 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: